In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Novo Nordisk, Innate target natural killer cells

Executive Summary

Cancer immunotherapeutics company Innate Pharma and Novo Nordisk have extended their three-year-old collaboration--began in 2003--by another three years to research and develop drugs that target natural killer (NK) cells in the body. Under the new agreement, the companies have expanded the scope of therapeutic areas to include infectious diseases and autoimmune disorders in addition to the originally focused area of cancer.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
      • Antibodies
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Equity
    • Intra-Biotech Deal
    • R&D and Marketing (Licensing)

Related Companies